Bivalent HPV vaccine shows benefit for recalcitrant warts

  • J Am Acad Dermatol

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Intralesional or intramuscular administration of a recombinant bivalent human papillomavirus (HPV) vaccine (Ceravix) appears effective for the treatment of patients with multiple recalcitrant common warts.

Why this matters

  • Warts are often recalcitrant to common treatments, necessitating new options.

Key results

  • 81.8% of patients treated with intralesional bivalent HPV vaccine and 63.3% of patients treated with intramuscular bivalent HPV vaccine achieved complete clearance (P=.287).
  • The clearance rate was faster in the intralesional group compared with the intramuscular group (3.22 vs 4.57 months; P=.005).
  • All patients reported tolerable pain at the injection site.
  • Localized itching was reported in 90.9% of the intralesional group and 95.5% of the intramuscular group.
  • No recurrences were reported during a 6-month follow-up.

Study design

  • 44 patients with recalcitrant multiple common warts (>2 years duration with no response to ≥2 treatment modalities), 22 who received intralesional bivalent HPV vaccine and 22 who received intramuscular bivalent HPV vaccine, were included.
  • Funding: None.

Limitations

  • Small sample size.
  • No control group.